A new research investigation using breast cancer cell models discovered that administering therapy with four readily accessible CO-RMs including CO-RM-1, CO-RM-2, CO-RM-3, and CO-RM-A1, significantly reduced the levels of excreted VEGF in these breast cancer cells, with CO-RM-2 showing the highest efficiency followed by CO-RM-3 [34]. This evidence concerns the gene VEGFA and breast cancer.